Abstract:Abstract When introduced for advanced BRAF-V600E-positive melanoma in 2011, BRAF inhibitor monotherapy cutaneous adverse effects included development of cutaneous squamous cell carcinoma (cSCC), eruptive melanocytic naevi (EMN) and melanoma. These risks became significantly less common when combination BRAF inhibitor/MEK inhibitor therapy became standard of care. However, in recent years BRAF inhibitor monotherapy is once again being used for other BRAF-V600E-positive malignancies. We report the first case of florid EMN developing on encorafenib BRAF inhibitor monotherapy for colorectal cancer, which dramatically regressed upon its withdrawal. A 62-year-old female patient with BRAF-V600E metastatic colorectal cancer was started on dual cetuximab (epidermal growth factor receptor inhibitor) and encorafenib therapy. Within 2–3 months > 40 new darkly pigmented melanocytic naevi had developed on her palms, soles, face and trunk. None were clinically or dermoscopically suspicious for melanoma. Treatment was continued given the initial partial response of the colorectal tumour. However, by 6 months this had progressed; cetuximab and encorafenib were stopped and chemotherapy started with FOLFIRI (folinic acid, fluorouracil and irinotecan). Within 2–3 months of encorafenib withdrawal, the EMN were involuting. Twelve months after stopping encorafenib, there had been almost complete involution of all EMN while pre-existing naevi remained stable. Excisional biopsy of a regressing lesion confirmed a benign melanocytic naevus with no dysplasia. Encorafenib is a highly selective RAF kinase inhibitor, which blocks the activated downstream mitogen-activated protein kinase (MAPK)-signalling pathway in BRAF-V600E mutant cells. However, in BRAF-wildtype melanocytes, BRAF-inhibitor monotherapy can cause paradoxical activation of MAPK signalling, promoting melanocytic hyperproliferation and development of new melanocytic naevi, EMN and primary melanomas. It is postulated that with ongoing BRAF inhibitor exposure, EMN become dependent upon activated MAPK signalling. This view is supported by reports of BRAF inhibitor monotherapy-associated EMN that subsequently undergo involution when MEK inhibitors are started. However, to our knowledge, there are no reports of spontaneous involution of EMN when BRAF inhibitor monotherapy alone is stopped, as in our case. This may not have been evident in historic cohorts of patients with advanced melanoma who had poor survival rates once BRAF inhibitor resistance developed. We hypothesize that EMN involution reflects reversal rather than blockade of MAPK pathway activation. In summary, we report the first case of EMN associated with BRAF inhibitor monotherapy to demonstrate complete involution upon treatment withdrawal. Given increasing use of BRAF inhibitor monotherapy as part of treatment regimens for patients with BRAF-V600E-positive cancers other than melanoma, this is likely to become a more common problem in the future. These risks will potentially extend to invasive cSCC and melanoma and highlight the central importance of supportive dermato-oncology expertise in ensuring clinician and patient awareness and appropriate ongoing skin surveillance.

PA21 A child with longitudinal melanonychia secondary to subungual naevus showing regression during treatment with a single-agent MEK inhibitor (trametinib)

Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report

BI04 Erupting and spontaneously vanishing moles in a new cohort of patients on BRAF inhibitor monotherapy

Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma

Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome

A rare cutaneous infection with Mycobacterium chelonae in a pediatric patient treated with trametinib for KRAS‐mutated diffuse glioma

Case report: Treatment response of NF-1-associated bladder ganglioneuroma to trametinib

Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition

P18 Giant Periocular Juvenile Xanthogranulomas Treated with Trametinib

Combinatorial effects of azacitidine and trametinib on NRAS‐mutated melanoma

New features in MEK retinopathy

Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome

Case report: MEK inhibitor as treatment for multi-lineage mosaic KRAS G12D-associated epidermal nevus syndrome in a pediatric patient

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAF V600 /NRAS Q61 Wild-Type Melanoma (TraMel-WT)

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)

Continuous response despite reduced dose of trametinib as single agent in an adolescent with a relapsed disseminated pediatric low-grade glioma KIAA1549-BRAF fusion positive: a case report and review of the literature

CNSC-12. NEURONAL DIFFERENTIATION DRIVES THE ANTI-TUMOR EFFICACY OF MEK INHIBITION IN GLIOBLASTOMA

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Biom-42. Response To Dabrafenib/Trametinib In A Patient With Who-Cns Grade 3 Braf V600E-Mutated Pleomorphic Xanthoastrocytoma

A Case of Class 3 MEK1 Mutated Metastatic Colorectal Cancer with a Non-Durable Tumor Marker Response to MEK and ERK Inhibitors

Cellular and Molecular Mechanisms of MEK1 Inhibitor-Induced Cardiotoxicity